Center of molecular immunology

The Center of Molecular Immunology (Centro de Immunología Molecuar) or CIM, is a cancer research institution located on the west side of Havana, Cuba. Opened on December 5, 1994, it focuses on the research and production of new biopharmaceutical products for the treatment of cancer and other nontransmissible diseases.

Additional recommended knowledge

Safe Weighing Range Ensures Accurate Results

Daily Visual Balance Check

What is the Correct Way to Check Repeatability in Balances?

Facilities

The design and construction of the Center of Molecular Immunology was modeled on current Good Manufacturing Practice guidelines recommended by the World Health Organization and adopted by Cuba, particularly those also adopted by the member countries of the European Union, then known as the European Community.

Research labs, production areas and administrative offices share the 15,000 square meters of the two floor facility.

Approximately 400 employees work at the CIM, most of them scientists and engineers. These personnel are administratively organized in three main areas: Research and Development, Production, and Quality Assurance.

Research

Basic research projects are focused on cancer immunotherapy, especially the development of molecular vaccines. These include antibody engineering, cellular engineering, bioinformatics and regulation of the immune response.

CIM conducts clinical trials in diagnostic imaging and cancer therapy of varying origin, as well as other immune system diseases, in highly specialized hospitals.

Products

Today CIM produces biopharmaceutical products, such as anti-CD3 monoclonal antibody for the treatment of patients with organ transplant rejection, human recombinant erythropoietin for the treatment of anemia, granulocyte colony-stimulating factor for the treatment of neutropenia, and a humanized monoclonal antibody that recognizes the epidermal growth factor receptor for cancer treatment, as well as other monoclonal antibodies for tumor imaging.

Commercialization

Since 1992 CIMAB S.A. has been devoted to the commercialization of biopharmaceutical products for the Cuban market and abroad, especially monoclonal antibodies and other recombinant proteins for the diagnosis and treatment of cancer and other diseases related to the immune system.

CIMAB S.A. is the exclusive representative for the commercialization of the products and services of the Center of Molecular Immunology.

References

• Official website of Center of Molecular Immunolgy. See External links.

See also

• Healthcare of Cuba
• The Pediatric Cancer Research Foundation